GRC 27864

Drug Profile

GRC 27864

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Analgesics; Anti-inflammatories; Antirheumatics
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation; Pain

Most Recent Events

  • 30 Sep 2016 Clinical trials in Inflammation in France (PO) before September 2016 (Glenmark Pharmaceuticals pipeline, January 2017 and quarterly report of September 2016)
  • 30 Sep 2016 Clinical trials in Pain in France (PO) before September 2016 (Glenmark Pharmaceuticals pipeline, January 2017 and quarterly report of September 2016)
  • 30 Sep 2016 Glenmark Pharmaceuticals completes a bioavailability clinical trial in Inflammation and Pain in France (Glenmark Pharmaceuticals pipeline, January 2017 and quarterly report of September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top